vs
Enact Holdings, Inc.（ACT）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Enact Holdings, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$312.7M vs $199.9M），Enact Holdings, Inc.同比增速更快（3.6% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ACT vs APLS — 直观对比
营收规模更大
ACT
是对方的1.6倍
$199.9M
营收增速更快
ACT
高出9.6%
-5.9%
两年增速更快
APLS
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $199.9M |
| 净利润 | — | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | 71.3% | -25.6% |
| 净利率 | — | -29.5% |
| 营收同比 | 3.6% | -5.9% |
| 净利润同比 | — | -62.2% |
| 每股收益（稀释后） | $1.23 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTAPLS
| Q4 25 | $312.7M | $199.9M | ||
| Q3 25 | $311.5M | $458.6M | ||
| Q2 25 | $304.9M | $178.5M | ||
| Q1 25 | $306.8M | $166.8M | ||
| Q4 24 | $301.8M | $212.5M | ||
| Q3 24 | $309.6M | $196.8M | ||
| Q2 24 | $298.8M | $199.7M | ||
| Q1 24 | $291.6M | $172.3M |
净利润ACTAPLS
| Q4 25 | — | $-59.0M | ||
| Q3 25 | — | $215.7M | ||
| Q2 25 | — | $-42.2M | ||
| Q1 25 | — | $-92.2M | ||
| Q4 24 | — | $-36.4M | ||
| Q3 24 | — | $-57.4M | ||
| Q2 24 | — | $-37.7M | ||
| Q1 24 | — | $-66.4M |
营业利润率ACTAPLS
| Q4 25 | 71.3% | -25.6% | ||
| Q3 25 | 67.4% | 48.7% | ||
| Q2 25 | 70.4% | -18.6% | ||
| Q1 25 | 68.9% | -50.0% | ||
| Q4 24 | 68.9% | -12.3% | ||
| Q3 24 | 74.1% | -24.0% | ||
| Q2 24 | 78.6% | -14.7% | ||
| Q1 24 | 70.6% | -36.0% |
净利率ACTAPLS
| Q4 25 | — | -29.5% | ||
| Q3 25 | — | 47.0% | ||
| Q2 25 | — | -23.6% | ||
| Q1 25 | — | -55.3% | ||
| Q4 24 | — | -17.1% | ||
| Q3 24 | — | -29.2% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -38.5% |
每股收益（稀释后）ACTAPLS
| Q4 25 | $1.23 | $-0.40 | ||
| Q3 25 | $1.10 | $1.67 | ||
| Q2 25 | $1.11 | $-0.33 | ||
| Q1 25 | $1.08 | $-0.74 | ||
| Q4 24 | $1.05 | $-0.30 | ||
| Q3 24 | $1.15 | $-0.46 | ||
| Q2 24 | $1.16 | $-0.30 | ||
| Q1 24 | $1.01 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $466.2M |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $370.1M |
| 总资产 | $6.9B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTAPLS
| Q4 25 | $582.5M | $466.2M | ||
| Q3 25 | $545.6M | $479.2M | ||
| Q2 25 | $616.0M | $370.0M | ||
| Q1 25 | $639.0M | $358.4M | ||
| Q4 24 | $602.8M | $411.3M | ||
| Q3 24 | $674.9M | $396.9M | ||
| Q2 24 | $711.3M | $360.1M | ||
| Q1 24 | $624.3M | $325.9M |
总债务ACTAPLS
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | $93.1M |
股东权益ACTAPLS
| Q4 25 | $5.4B | $370.1M | ||
| Q3 25 | $5.3B | $401.2M | ||
| Q2 25 | $5.2B | $156.3M | ||
| Q1 25 | $5.1B | $164.2M | ||
| Q4 24 | $5.0B | $228.5M | ||
| Q3 24 | $5.0B | $237.1M | ||
| Q2 24 | $4.8B | $264.3M | ||
| Q1 24 | $4.7B | $266.7M |
总资产ACTAPLS
| Q4 25 | $6.9B | $1.1B | ||
| Q3 25 | $6.9B | $1.1B | ||
| Q2 25 | $6.8B | $821.4M | ||
| Q1 25 | $6.7B | $807.3M | ||
| Q4 24 | $6.5B | $885.1M | ||
| Q3 24 | $6.6B | $901.9M | ||
| Q2 24 | $6.3B | $904.5M | ||
| Q1 24 | $6.3B | $831.9M |
负债/权益比ACTAPLS
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-14.3M |
| 自由现金流率自由现金流/营收 | — | -7.1% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $45.0M |
8季度趋势，按日历期对齐
经营现金流ACTAPLS
| Q4 25 | $724.5M | $-14.2M | ||
| Q3 25 | $192.0M | $108.5M | ||
| Q2 25 | $119.5M | $4.4M | ||
| Q1 25 | $226.7M | $-53.4M | ||
| Q4 24 | $686.3M | $19.4M | ||
| Q3 24 | $188.1M | $34.1M | ||
| Q2 24 | $144.7M | $-8.3M | ||
| Q1 24 | $187.3M | $-133.0M |
自由现金流ACTAPLS
| Q4 25 | — | $-14.3M | ||
| Q3 25 | — | $108.3M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-8.4M | ||
| Q1 24 | — | $-133.3M |
自由现金流率ACTAPLS
| Q4 25 | — | -7.1% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | -32.0% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -4.2% | ||
| Q1 24 | — | -77.3% |
资本支出强度ACTAPLS
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.2% |
现金转化率ACTAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
